Aspirin 300 mg - search results

New Zealand - English - Medsafe (Medicines Safety Authority)

soluble aspirin bp

psm healthcare ltd trading as api consumer brands - aspirin 300mg - soluble tablet - 300 mg - active: aspirin 300mg excipient: calcium carbonate citric acid monohydrate isopropyl alcohol purified talc saccharin sodium sodium laurilsulfate wheat starch

Australia - English - Department of Health (Therapeutic Goods Administration)

apo-clopidogrel/aspirin 75/75 clopidogrel (as hydrogen sulfate)/aspirin 75 mg/75 mg tablet blister pack

arrotex pharmaceuticals pty ltd - clopidogrel hydrogen sulfate, quantity: 97.88 mg; aspirin, quantity: 75 mg - tablet, film coated - excipient ingredients: maize starch; methylcellulose; hyprolose; zinc stearate; lactose; iron oxide yellow; crospovidone; microcrystalline cellulose; macrogol 8000; colloidal anhydrous silica; hypromellose; titanium dioxide - clopidogrel/aspirin is a fixed dose combination product. clopidogrel/aspirin is intended as continuation of therapy in patients with acute coronary syndrome already initiated with separate clopidogrel and aspirin products:,? unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). clopidogrel/aspirin is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent).,? st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, clopidogrel/aspirin has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.